135 related articles for article (PubMed ID: 28413418)
1. Study of the regulatory promoter polymorphism (-938C>A) of B-cell lymphoma 2 gene in breast cancer patients of Mazandaran province in Northern Iran.
Moghaddam SE; Barzegar A; Nikbakhsh N
J Res Med Sci; 2017; 22():21. PubMed ID: 28413418
[TBL] [Abstract][Full Text] [Related]
2. Influence of BCL2-938 C>A promoter polymorphism and BCL2 gene expression on the progression of breast cancer.
Bhushann Meka P; Jarjapu S; Vishwakarma SK; Nanchari SR; Cingeetham A; Annamaneni S; Mukta S; Triveni B; Satti V
Tumour Biol; 2016 May; 37(5):6905-12. PubMed ID: 26662799
[TBL] [Abstract][Full Text] [Related]
3. BCL-2 (-938C > A) polymorphism is associated with breast cancer susceptibility.
Zhang N; Li X; Tao K; Jiang L; Ma T; Yan S; Yuan C; Moran MS; Liang F; Haffty BG; Yang Q
BMC Med Genet; 2011 Apr; 12():48. PubMed ID: 21457555
[TBL] [Abstract][Full Text] [Related]
4. The AA genotype of the regulatory BCL2 promoter polymorphism ( 938C>A) is associated with a favorable outcome in lymph node negative invasive breast cancer patients.
Bachmann HS; Otterbach F; Callies R; Nückel H; Bau M; Schmid KW; Siffert W; Kimmig R
Clin Cancer Res; 2007 Oct; 13(19):5790-7. PubMed ID: 17908970
[TBL] [Abstract][Full Text] [Related]
5. The bcl2 -938CC genotype has poor prognosis and lower survival in renal cancer.
Hirata H; Hinoda Y; Nakajima K; Kikuno N; Suehiro Y; Tabatabai ZL; Ishii N; Dahiya R
J Urol; 2009 Aug; 182(2):721-7. PubMed ID: 19539330
[TBL] [Abstract][Full Text] [Related]
6. Association of BCL2-938C>A genetic polymorphism with glioma risk in Chinese Han population.
Li W; Qian C; Wang L; Teng H; Zhang L
Tumour Biol; 2014 Mar; 35(3):2259-64. PubMed ID: 24287948
[TBL] [Abstract][Full Text] [Related]
7. Association of a novel regulatory polymorphism (-938C>A) in the BCL2 gene promoter with disease progression and survival in chronic lymphocytic leukemia.
Nückel H; Frey UH; Bau M; Sellmann L; Stanelle J; Dürig J; Jöckel KH; Dührsen U; Siffert W
Blood; 2007 Jan; 109(1):290-7. PubMed ID: 16960146
[TBL] [Abstract][Full Text] [Related]
8. Influence of BCL2-938C>A and BAX-248G>A promoter polymorphisms in the development of AML: case-control study from South India.
Cingeetham A; Vuree S; Dunna NR; Gorre M; Nanchari SR; Edathara PM; Meka P; Annamaneni S; Digumarthi R; Sinha S; Satti V
Tumour Biol; 2015 Sep; 36(10):7967-76. PubMed ID: 25957891
[TBL] [Abstract][Full Text] [Related]
9. The regulatory BCL2 promoter polymorphism (-938C>A) is associated with relapse and survival of patients with oropharyngeal squamous cell carcinoma.
Lehnerdt GF; Franz P; Bankfalvi A; Grehl S; Kelava A; Nückel H; Lang S; Schmid KW; Siffert W; Bachmann HS
Ann Oncol; 2009 Jun; 20(6):1094-9. PubMed ID: 19196738
[TBL] [Abstract][Full Text] [Related]
10. CC genotype of anti-apoptotic gene BCL-2 (-938 C/A) is an independent prognostic marker of unfavorable clinical outcome in patients with non-small-cell lung cancer.
Javid J; Mir R; Mirza M; Imtiyaz A; Prasant Y; Mariyam Z; Julka PK; Mohan A; Lone M; Ray PC; Saxena A
Clin Transl Oncol; 2015 Apr; 17(4):289-95. PubMed ID: 25257838
[TBL] [Abstract][Full Text] [Related]
11. Association of CYP1A1 M2 (A2455G) Polymorphism with Susceptibility to Breast Cancer in Mazandaran Province, Northern Iran: A Case-control Study.
Khalili-Tanha G; Barzegar A; Nikbakhsh N; Ansari-Pirsaraei Z
Int J Prev Med; 2019; 10():92. PubMed ID: 31360339
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of
Al-Zubaidy HFS; Majeed SR; Al-Koofee DAF
Arch Razi Inst; 2022 Apr; 77(2):799-808. PubMed ID: 36284943
[TBL] [Abstract][Full Text] [Related]
13. Association of the AA genotype of the BCL2 (-938C>A) promoter polymorphism with better survival in ovarian cancer.
Heubner M; Wimberger P; Otterbach F; Kasimir-Bauer S; Siffert W; Kimmig R; Nückel H
Int J Biol Markers; 2009; 24(4):223-9. PubMed ID: 20082279
[TBL] [Abstract][Full Text] [Related]
14. Regulatory BCL2 promoter polymorphism (-938C>A) is associated with adverse outcome in patients with prostate carcinoma.
Bachmann HS; Heukamp LC; Schmitz KJ; Hilburn CF; Kahl P; Buettner R; Nückel H; Eisenhardt A; Rübben H; Schmid KW; Siffert W; Eggert A; Schramm A; Schulte JH
Int J Cancer; 2011 Nov; 129(10):2390-9. PubMed ID: 21207420
[TBL] [Abstract][Full Text] [Related]
15. Polymorphisms in Phase I (CYP450) Genes
Golmohammadzadeh G; Mohammadpour A; Ahangar N; Shokrzadeh M
Open Access Maced J Med Sci; 2019 Aug; 7(15):2488-2496. PubMed ID: 31666853
[TBL] [Abstract][Full Text] [Related]
16. Association of the CC genotype of the regulatory BCL2 promoter polymorphism (-938C>A) with better 2-year survival in patients with glioblastoma multiforme.
El Hindy N; Bachmann HS; Lambertz N; Adamzik M; Nückel H; Worm K; Zhu Y; Sure U; Siffert W; Sandalcioglu IE
J Neurosurg; 2011 Jun; 114(6):1631-9. PubMed ID: 21250804
[TBL] [Abstract][Full Text] [Related]
17. BCL2 genotypes and prostate cancer survival.
Renner W; Langsenlehner U; Krenn-Pilko S; Eder P; Langsenlehner T
Strahlenther Onkol; 2017 Jun; 193(6):466-471. PubMed ID: 28396899
[TBL] [Abstract][Full Text] [Related]
18. The BCL2 -938C>A Promoter Polymorphism Is Associated with Risk for and Time to Aseptic Loosening of Total Hip Arthroplasty.
Stelmach P; Wedemeyer C; Fuest L; Kurscheid G; Gehrke T; Klenke S; Jäger M; Kauther MD; Bachmann HS
PLoS One; 2016; 11(2):e0149528. PubMed ID: 26881923
[TBL] [Abstract][Full Text] [Related]
19. ATM, BCL2, and TGFβ Gene Polymorphisms as Radiotherapy Outcome Biomarkers in Head and Neck Squamous Cell Carcinoma Patients.
Agostini LP; Stur E; Garcia FM; Ventorim DP; Dos Reis RS; Dettogni RS; Dos Santos EVW; Peterle GT; Maia LL; Mendes SO; de Carvalho MB; Tajara EH; de Paula F; Dos Santos M; da Silva AMA; Louro ID
Genet Test Mol Biomarkers; 2017 Dec; 21(12):727-735. PubMed ID: 29135311
[TBL] [Abstract][Full Text] [Related]
20. The -938A/A genotype of BCL2 gene is associated with esophageal cancer.
Liu Z; Sun R; Lü W; Dang C; Song Y; Wang C; Zhang X; Han L; Cheng H; Gao W; Liu J; Lei G
Med Oncol; 2012 Dec; 29(4):2677-83. PubMed ID: 22187149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
